The scale of insider buying—over $159M at $16/share—represents a strong vote of confidence, especially from a director and major shareholder. Traders should monitor for follow-up commentary or filings that may confirm positive developments ahead of upcoming catalysts.
Price Chart
Executive Summary
Two insiders, including a director and major shareholder, collectively purchased $159.38 million of Kailera Therapeutics stock at $16 per share, signaling strong confidence in the company's prospects. The transactions occurred alongside routine non-cash equity grants and conversions, but the open-market buying is highly material.
Key Financial Metrics
Key Facts
- Bain Capital Life Sciences Investors purchased 1.56 million shares for $25 million in open-market transactions.
- Director and 10% owner Andrew T. Kaplan bought 8.40 million shares for $134.38 million at $16 per share.
- Total open-market purchases amount to $159.38 million, all occurring on April 20, 2026.
- Numerous non-cash transactions (grants, conversions) were reported on April 16, which are routine and non-material.
- Both buyers are significant stakeholders, amplifying the signal of confidence.
Financial Impact
$159.38 million in open-market purchases by two insiders
Risk Factors
- The purchases could precede a dilutive offering or secondary announcement.
- Concentration risk given that both major buyers are already large stakeholders.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KLRA-1776722536109 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access